CDKN2A and Ewing sarcoma: Although we defined actionability with respect to genomically matched targeted therapies, genomic findings can inform clinical action in other ways, including informing prognosis (e.g. TP53, CDKN2A, and STAG2 in pediatric Ewing sarcoma)21,72.